Recently, the clinical relevance of CTCs in metastatic cancers has been clearly demonstrated in multiple types of advanced cancer including breast cancer, prostate cancer and colon cancer, where CTC detection has been significantly enhanced by the development of EpCAM-based enrichment strategies [2-4]. The gene discussed is EPCAM; the disease is prostate carcinoma.